Deramiocel Published in The Lancet; LVEF Model Updated; FDA BIMO Inspection Completed with One Observation

summarizeSummary

Deramiocel Phase 3 results published in The Lancet, but an updated statistical model weakened the LVEF secondary endpoint significance. FDA BIMO inspection completed with one observation. PDUFA date is August 22, 2026.

check_boxKey Events · Product Development and Regulatory · CAPR

• HOPE-3 Published in The Lancet

  The pivotal Phase 3 trial met its primary endpoint, showing a 54% slowing of upper limb function decline (PUL 2.0, p=0.03). Publication in a top-tier journal provides external peer-review validation.

• LVEF Statistical Model Updated

  The key secondary endpoint, left ventricular ejection fraction (LVEF), now shows p=0.09 (1.8 pp treatment difference) vs previously reported p=0.04 (2.4 pp difference). In the cardiomyopathy subgroup, it remains nominally significant at p=0.02 (2.8 pp difference).

• FDA BIMO Inspection Completed

  A Bioresearch Monitoring inspection of clinical operations concluded July 20, 2026, with one Form 483 observation related to SOPs, documentation, vendor oversight, and audit report timeliness. Company states it does not affect data integrity.

• PDUFA Target Action Date August 22, 2026

  The BLA remains under active FDA review, with an Advisory Committee meeting scheduled for July 29, 2026 (today). The PDUFA date is less than one month away.

auto_awesomeAnalysis · CAPR · Life Sciences

External validation arrives for Capricor's pivotal HOPE-3 Phase 3 data on Deramiocel in Duchenne muscular dystrophy, now published in The Lancet, a top-tier peer-reviewed journal. The trial met its primary endpoint with a 54% slowing of upper limb function decline (p=0.03). However, an updated statistical model for the key secondary endpoint, left ventricular ejection fraction (LVEF), now yields p=0.09 (1.8 percentage point treatment difference) versus the previously reported p=0.04 (2.4 percentage point difference). While the primary endpoint and all other data remain unchanged, the weakened LVEF significance could draw scrutiny at the upcoming Advisory Committee meeting. Separately, the FDA completed a BIMO inspection of clinical operations, issuing one Form 483 observation related to SOPs, documentation, vendor oversight, and audit report timeliness. The company does not believe this affects data integrity. With the PDUFA date of August 22, 2026, approaching, these developments are critical for the approval outlook.